Format

Send to

Choose Destination
J Am Pharm Assoc (2003). 2019 Aug 9. pii: S1544-3191(19)30342-5. doi: 10.1016/j.japh.2019.07.006. [Epub ahead of print]

Access to treatment among persons with hemophilia: A spatial analysis assessment in the Rhone-Alpes region, France.

Abstract

OBJECTIVES:

In France, only hospital pharmacies can dispense clotting factor concentrates to persons with hemophilia, which limits the access to care for the treatment and the prevention of bleeding episodes. Moreover, the cost of clotting factor concentrates may restrain the maintenance of sufficient stocks in hospital pharmacies. The aim of this study was to investigate the accessibility of clotting factor concentrates to persons with hemophilia in the context of long-term prophylaxis and emergency treatment in the Rhone-Alpes region of France.

METHODS:

A geographic information system was used for evaluating accessibility of clotting factor concentrates. Persons with hemophilia and hospital pharmacies were geolocalized with the use of postal data, and the evaluation of accessibility was based on the road network.

RESULTS:

Approximately 72% of the study area was accessible in less than 30 minutes to a hospital pharmacy. Eighty-five percent of persons with hemophilia had access to clotting factor concentrates for prophylactic treatment in less than 20 minutes. Most of them were patients with severe or moderate hemophilia. Regarding emergency doses, factor VIII was accessible in less than 30 minutes in 45.6% of the study area, and factor IX in 30.5%.

CONCLUSION:

This study highlights that spatial access to clotting factor concentrates by persons with hemophilia in the Rhône-Alpes region is good for prophylactic treatment but is more uneven for emergency doses.

PMID:
31405805
DOI:
10.1016/j.japh.2019.07.006

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center